ArticleMolecular diversity2026
Total synthesis of the proposed menominin A and its stereoisomers: identification of a highly potent isomer (1a) against RM-1 prostate cancer cells.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating network pharmacology, molecular dynamics, and in vitro assays to unveil the mechanism of costunolide against gastric cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Menominin A is a natural cyclodepsipeptide isolated from the freshwater sponge-associated cyanobacterium Nostoc sp. UIC 10,607, and exhibits antiproliferative activity against the high-grade serous ovarian cancer cell line OVCAR3. The pronounced biological relevance and limited natural abundance have rendered menominin A a compelling target for total synthesis and biological studies. Herein, we report the total synthesis and cytotoxicity evaluation of the proposed structure of menominin A and its seven isomers. Key features of this synthesis include an Evans aldol reaction to construct the 3-hydroxy-2-methylcarboxylic acid unit, a chiral phosphonic acid-mediated asymmetric allylic addition to establish a chiral alcohol, and a ring-closing metathesis followed by hydrogenation to construct the macrocyclic framework. The mismatch between the NMR spectra of our synthetic samples and those of the natural product suggests that the originally proposed structure is incorrect. Biological evaluation indicated that three compounds (1a, 1b, and 1g) displayed moderate to potent antitumor activity against osteosarcoma, human colon cancer, and prostate cancer. The most active compound 1a exhibited antiproliferative activity against RM-1 cells in a sustained manner, yielding IC
Indexed as
Identifiers
42360584What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.